In particular, thePA reported that the inhibition of POLθ is SL to cancer cellsthat are resistant to PARP inhibition through loss of Shieldin components,a finding with significant implications for the treatment of cancerpatients bearing tumors that are resistant to PARPi -based therapies. This evidence concerns the gene PARP1 and cancer.